After its announcement of a modest increase in second quarter revenues, BioMarin outlined plans for its hemophilia A gene therapy candidate valrox, or valoctocogene roxaparvovec, including the submission of marketing applications in the US and Europe.
BioMarin shares plans for hemophilia A gene therapy candidate valrox
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.